Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
January 07 2021 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that Corinne Le Goff, Pharm.D., MBA, will join Moderna as Chief
Commercial Officer effective Tuesday, January 19, 2021. She will
serve on Moderna’s Executive Committee and report to Chief
Executive Officer Stéphane Bancel.
“I am thrilled to welcome Corinne to Moderna as our Chief
Commercial Officer and to the Executive Committee. Corinne is
joining us at an important time as we launch our COVID-19 vaccine,
prepare to start the Phase 3 study of our CMV vaccine and pivot to
a commercial stage company,” said Stéphane Bancel, Chief Executive
Officer of Moderna. “Corinne’s impressive track record of execution
and leading high-performing teams at global biopharma companies
including Amgen and Roche, as well as her passion for creating
value through scientific innovation, will position Moderna well as
we continue building a best-in-class commercial team.”
Dr. Le Goff comes to Moderna from Amgen (Nasdaq: AMGN), where
she served as SVP and President of the U.S. Business Organization.
In this role, she was credited with the valuation and the
successful commercial integration of Otezla®1, and for driving the
growth strategy with increased contributions from Repatha®2 and
Aimovig®3. During her nearly 6-year tenure at Amgen, she also
served as SVP of the Europe Region and oversaw 48 markets. Dr. Le
Goff was actively engaged with the policy community and advocates
for innovative, high-quality and affordable healthcare. She
represented Amgen as a member of the Healthcare Leadership
Council.
Prior to joining Amgen, Dr. Le Goff held a number of senior
international roles at Roche (SWX: RO) including President of Roche
France, a major affiliate of the Roche Group, and Global Product
Strategy Head of Neuroscience & Rare Diseases. Earlier in her
career, Dr. Le Goff spent 11 years in various leadership roles at
Sanofi (Nasdaq: SNY) and Pfizer (NYSE: PFE) in the United
States.
“I am delighted to join Moderna at this crucial time of the
launch of the Moderna COVID-19 Vaccine, as the company pivots to
becoming a global commercial organization,” said Dr. Le Goff. “The
Moderna technology is game-changing and will undoubtedly disrupt
the traditional biotechnology world and in time lead to
life-altering therapies.”
Dr. Le Goff is a Director of CFAO, a trading company that
operates in 36 markets in Africa. Dr. Le Goff received a Doctorate
in Pharmacy from Rene Descartes University in Paris and a Master of
Business Administration from La Sorbonne University and INSEAD.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and BARDA. Moderna has been named a top biopharmaceutical
employer by Science for the past six years. To learn more, visit
www.modernatx.com.
1 Otezla® is a registered trademark of Amgen
2 Repatha® is a registered trademark of Amgen
3 Aimovig® is a registered trademark of Amgen
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210107005510/en/
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com Investors: Lavina
Talukdar Senior Vice President & Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024